Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 10/20 | 0.51 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011834 | 0.89 | NTRK1 (0.61) | JAK2NTRK1NUAK1JAK3IGF1R | |
| SCHEMBL3134412 | 0.87 | NTRK1 (0.58) | JAK2NTRK1NUAK1JAK3IGF1R | |
| SCHEMBL3134400 | 0.87 | NTRK1 (0.58) | JAK2NTRK1NUAK1JAK3IGF1R | |
| SCHEMBL3133640 | 0.86 | NTRK1 (0.56) | JAK2NTRK1JAK3 | |
| SCHEMBL3023780 | 0.83 | NTRK1 (0.45) | JAK2NTRK1JAK3 | |
| SCHEMBL3029292 | 0.83 | NTRK1 (0.44) | JAK2NTRK1JAK3 | |
| SCHEMBL3124301 | 0.79 | NUAK1 (0.68) | JAK2NTRK1NUAK1JAK3IGF1R | |
| SCHEMBL3124294 | 0.79 | NUAK1 (0.68) | JAK2NTRK1NUAK1JAK3IGF1R | |
| SCHEMBL3126574 | 0.78 | NUAK1 (0.56) | JAK2NTRK1NUAK1JAK3 | |
| SCHEMBL3126595 | 0.78 | NUAK1 (0.56) | JAK2NTRK1NUAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ABL1, MCL1, ETV6 | JAK2 4/4885NTRK1 4243/4885NUAK1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.